A Seamless Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia in China
Latest Information Update: 05 Jun 2023
Price :
$35 *
At a glance
- Drugs Tafolecimab (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Therapeutic Use
- 07 Jul 2021 New trial record